Strand Genomics Launches In Silico ADMET Tool
News Sep 08, 2005
Strand has announced the launch of its in silico predictive ADMET tool, admetis. Strand has leveraged its core technologies to develop decision-support solutions for powering drug discovery including in silico predictive models for drug properties such as ADME and Cardiotoxicity.
Strand has an ongoing research program in predictive modeling for hepatotoxicity. Strand partners with discovery contract research companies in India to combine in silico with wet lab techniques to offer consulting services starting from compound design to lead generation.
"The change in corporate identity reflects the expanding focus of the company. Our portfolio of products now extends beyond functional genomics into computational chemistry," said Vijay Chandru, CEO and Chairman, Strand Life Sciences.
He adds, "admetis addresses a key need in the industry and can help profile compounds early."
admetis is a tool for modeling and predicting drug-relevant properties of molecules in silico. It is designed to give users the power to build custom models from scratch using their own data.
This is made possible through model-building workflows based on Strand's expertise in in silico model building.
admetis comes packaged with its pre-built models, truPK and truTox, for predicting Bioavailability, Protein binding, Volume distribution, Elimination half life, Rate of absorption and hERG binding.
admetis has an extensive data mining and visualization module that is designed to support an embedded chemical structure viewer.
"admetis couples pre-built models with a workflow-based modeling platform making it a distinct offering." said Kas Subramanian, CSO, Strand Life Sciences.
He adds, "admetis is a highly intuitive and easy to use tool that helps build accurate predictive models on the fly."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.